Partnering opportunity

A French pharmaceutical company is looking for projects targeting the resolution of inflammation phase in autoimmune or chronic immuno-inflammatory diseases

Summary

A French pharmaceutical company is interested to enrich its portfolio with early stage as well as preclinical or clinical candidates on autoimmune and immuno-inflammatory diseases. The company desires to engage in joint development, in-licensing or asset purchase partnerships and is primary interested by diseases such as Lupus, Primary Sjögren's syndrome and Systemic Sclerosis, and also by other autoimmune or chronic inflammatory diseases.

Technical Specification or Expertise Sought

The company is looking for new assets for the extension of its portfolio in chronic inflammatory diseases with similar physiopathological mechanisms: ₋ Downregulation of Th1 and/or Th17 immune responses; ₋ Upregulation of regulatory responses; ₋ Stimulation of resolution phase. The prerequisites for project validation are: ₋ Target rational (in vitro and/or in vivo); ₋ Evidence for translation to humans (target/pathway modulation under disease conditions and/or genetic); ₋ Evidence for target drug-ability and establishing of a robust compound testing flow-scheme; ₋ Rationale for differentiation to marketed drugs; ₋ Safety related to target/pathway modulation- Integrin extracellular ligands: collagen, elastin, polylysine, fibronectin, laminin, nidogens, osteopontin.

Partner sought

The French company is looking for academic or industrial partners. The size of the industrial partner is not important, it can be a startup or a mid-size company. The company is open to establish mid-to-long term partnerships with financial support. The type of partnership sought can be joint development, in-licensing or asset purchase. The therapeutic strategies promoted are peptides, antibodies, small molecules, gene therapy, cell therapy and such. Excluded are diagnostics technics (biomarkers), vaccines, services, e-health and medical device.

Description

This French international and independent pharmaceutical company, governed by a non-profit foundation, is focused on developing new therapies for unmet medical needs.As the 2nd French pharmaceutical company and the 30th worldwide, with 3 research centers and 16 production sites this French company has a global reach. With 33 drug candidates in clinical development, they are specialized in 5 major axes: cardiovascular diseases, diabetes, cancers, immune-inflammatory diseases and neuropsychiatric diseases. In the field of immuno-inflammatory and auto-immune diseases, the company is eager to establish new contacts and mid-to-long term partnerships with financial support helping partners to transform innovative projects into patient benefit. Besides extensive research facilities, they also have full capabilities to conduct clinical studies and to help get a new product marketed. The partnerships with projects are flexible in the deal structure: joint development, in-licensing or asset purchase. The first priorities are projects regarding Lupus, Sjögren's Syndrome, Systemic Sclerosis or any autoimmune or chronic inflammatory disease with related mechanisms. The targets are Th1/Th17 downregulation, Treg upregulation, stimulation of resolution phase of inflammation, any innovative pathway in our targeted diseases. The therapeutic strategies promoted are peptides, antibodies, small molecules, gene therapy, cell therapy and such. Excluded are diagnostics technics (biomarkers), vaccines, services, e-health and medical device. The projects can be from late exploratory target or pathway partly validated - with evidence from disease-relevant models to target to hit - to preclinical and clinical candidates. Projects from late exploratory (validated targets) to clinical phase II in the scope of resolution phase are included.

Advantages and innovations

Not available

Development stage

Not available

Intellectual Property Rights (IPR)

Not available


Register your interest

How it works

  • Tell us about yourself
  • We’ll discuss with you
  • We put the right partners in touch

EEN help you find the right partner, rather than you going it alone.

Our role is to review and collate the most suitable submissions, and then send them to the client who posted the opportunity. We consult with you, and the client, to make the process professional and easy.

These are live opportunities. Your registration of interest on the site is just like a professional approach to a business at a networking event. To stand the best chance of success, make your submission really sing. Sell why the client who posted the opportunity should work with you. Excite them. Ask questions. Try and avoid copy and pasting words from elsewhere.

Once the client has chosen their partner, we'll introduce them over email and keep in touch with both parties to see how it's going. Sometimes things progress quickly. Sometimes because of changing priorities for either party, things progress slowly, but you never know - your next big business break could start right here.

?What value does EEN add?
This is your pitch: remember to include your unique selling points (USP) and why someone would want to do business with you
Tell us why you are a good fit for this opportunity, and why you think you're the right people for this partnership
If there's anything additional, or commercially sensitive you'd like to know about this opportunity, please let us know

When you entered your email address above, we emailed you a code to verify you're human and have access to that account.

?What's this?

What next?

To finish up, we just need some extra details about you and your company